ARS Pharmaceuticals, Inc.
SPRY
$5.23
-$0.16-2.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.89% | -78.60% | -182.76% | -167.41% | -258.60% |
| Total Depreciation and Amortization | 49.10% | 41.79% | 1,337.93% | 1,761.90% | 1,450.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.53% | 100.36% | 79.66% | 170.99% | 321.63% |
| Change in Net Operating Assets | -1,018.03% | 182.54% | 30.11% | -137.22% | -130.55% |
| Cash from Operations | -53.89% | -10.32% | -203.53% | -225.20% | -443.92% |
| Capital Expenditure | -- | -- | 100.00% | -40.71% | -34.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.50% | -4.68% | 123.77% | -364.09% | 485.64% |
| Cash from Investing | -14.41% | -4.38% | 123.70% | -367.46% | 484.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.86% | -91.45% | 16.11% | -29.56% | 394.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -98.78% | -- | -- |
| Cash from Financing | 18.54% | -78.07% | -98.41% | 14,612.50% | 394.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -238.39% | -55.17% | -263.44% | 164.50% | 160.25% |